Barclays lowered the firm’s price target on Repligen (RGEN) to $175 from $200 and keeps an Overweight rating on the shares. The firm says the company is positioned to “beat and raise” this year given the setup and conservatism baked into its guidance.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN:
- Repligen Signals Confident Growth Path In 2026 Outlook
- Repligen: Cautious 2026 Guidance with Derisked Upside and Premium-Valuation Growth Justifying a Buy Rating
- Repligen reports Q4 adjusted EPS 49c, consensus 44c
- Repligen sees FY26 EPS $1.93-$2.01, consensus $2.07
- RGEN Earnings this Week: How Will it Perform?